| Primary information |
|---|
| ID | 1007 |
| Peptide Name | kalata B1 mutants [N29K] |
| Sequence | GLPVCGETCVGGTCNTPGCTCSWPVCTRK |
| Length | 29 |
| Chirality | L |
| N-terminal Modification | Addition of Cysteine |
| C-terminal Modification | Thioester linker |
| Chemical Modification | Three Disulfide linkage (CI-CIV, CII-CV and CIII-CVI) |
| Linear/ Cyclic | Cyclic (head to tail |
| Nature | Synthetic |
| Source of Origin | NA |
| Target | Reduction of the IL-2 surface receptor CD25 expression (79%±10 after 24 hrs and 46%±18 after 36 hrs), also reduces TNF-α expression (23%±11) |
| Mechanism of Action | Suppress T-cell polyfunctionality and arrest the proliferation of immune-competent cells through inhibiting IL-2 biology at more than one site as IL-2) surface receptor as well as IL-2 cytokine secretion and IL-2 gene expression. |
| In vitro/In vivo | In vitro |
| Cell Line | Human peripheral Lymphocytes |
| Inhibition Concentartion | 3.2±0.6 micromolar for Lymphocytes (PBMCs) |
| In vivo Model | NA |
| Assay | Cell Proliferation assay, Ca2+ release assay, Cytokines release assay |
| Lethal Dose | NA |
| Combination Therapy | NA |
| Pubmed ID | 23840803 |
| Year of Publication | 2013 |
| 3-D Structure | NA |
